

**INSTITUTIONAL BIOSAFETY COMMITTEE MEETING
PROVIDENCE PORTLAND MEDICAL CENTER
Minutes of April 7, 2026
Location: Virtual on Teams**

Attendees: (X) if absent

Will Redmond, PhD – Chair	Amy Greathouse (non-voting)	Melissa Kasiewicz (non-voting)	GUESTS: David Page, MD Tracy Kelley Nikki Moxon Stacy Mellinger Kari Copping
Matthew Philpott, PhD	Michael Munks, PhD (x)	Andrew Weinberg, PhD (x)	
Tacy Brotherton	Tong Zhang, PhD	Jennifer Wilk, DVM, DACLAM	
Angela Wang (x)			

Call To Order: The Institutional Biosafety Committee (IBC) Administrator called the meeting to order at 1:06pm . A quorum was present.

TOPIC	DISCUSSION / RESULTS	ACTION
<p>New Protocol Review: #174 A phase 3 study to confirm clinical benefit of SV-BR-1-GM, an experimental, HER-2/neu positive, allogeneic, whole cell breast tumor cell line transfected with the CSF2 gene to secrete GM-CSF in relapsed and refractory metastatic breast cancer patients.</p>	<p>NIH Guidelines Section: III-C-1</p> <p>The studies’ primary objective is to assess the safety and effectiveness of an experimental therapy for advanced breast cancer called Bria-IMT (SV-BR-1-GM) in combination with the immune checkpoint inhibitor, Retifanlimab.</p> <p>Committee discussed the study and had a few minor edits.</p> <ol style="list-style-type: none"> 1) I.1: Add III-C-1 and include any appendices; experiments are not exempt under III-F-8 and Appendix C-1. 2) III.14.: Amend with institute-specific suggested language. 3) IV.15.a./15.b./15.c.: Amend with institute-specific suggested language. 4) V.16.: Amend with institute-specific suggested language. 	<p>Motion to approve with administrative edits, seconded, and approved.</p>
Other Business	Review minutes from previous meeting on October 16, 2025.	Motion to approve; seconded; and approved.

Meeting adjourned at approximately 1:14pm.